 |
|
Methyldopa-Induced Immune Hemolytic Anemia and Chronic Active Hepatitis
Oded Shalev, MD;
Morris Mosseri, MD;
Ilana Ariel, MD;
Ruth Stalnikowicz, MD
Arch Intern Med. 1983;143(3):592-593.
Abstract
• Immune hemolytic anemia and chronic active hepatitis developed concurrently in a 76-year-old man after prolonged therapy with methyldopa. Both complications disappeared following cessation of treatment with the offending drug and a short course of a high-dose corticosteroid (prednisone). Inhibition of T-suppressor lymphocyte function by methyldopa may be instrumental in the emergence of autoimmune complications following usage of the drug.
(Arch Intern Med 1983;143:592-593)
Author Affiliations
From the Departments of Internal Medicine (Drs Shalev, Mosseri, and Stalnikowicz) and Pathology (Dr Ariel), Hadassah University Hospital, Mt Scopus, Jerusalem.
Footnotes
Accepted for publication Oct 12, 1982.
Reprint requests to Department of Internal Medicine, Hadassah Hospital, Mt Scopus, Jerusalem, Israel (Dr Shalev).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
Gleeson and Heneghan
Gut 2011;60:1611-1629.
ABSTRACT
| FULL TEXT
|
